Get More Information on Alzheimer’s Therapeutics Market - Request Sample Report
The Alzheimer’s Therapeutics Market Size was valued at USD 3.78 Billion in 2023 and will reach USD 13.42 Billion by 2032, with a growing CAGR of 15.14% during 2024-2032.
The rising prevalence of Alzheimer’s Disease is a significant factor that is boosting the Alzheimer’s therapeutics market. According to the National Institutes of Health, about 6.68 million Americans aged 65 and older suffered from Alzheimer’s in the US in 2023, a number that is projected to reach 13.8 million Americans by 2060. The higher incidence in women, as a result of their longer life expectancy, only intensifies the need for effective treatments. Currently, 1 in 9 people aged 65 and older has Alzheimer’s. and approx. two-thirds of Americans suffering from Alzheimer’s are women. The approval of disease-modifying therapies is another key factor contributing to market growth. Disease-modifying therapies offer hope for slowing disease progression, filling a huge gap in the current treatment landscape.
In addition, cloud-based cognitive assessment systems, for example, Cambridge Cognition’s Cantab Connect, make it easy for pharmaceutical companies to precisely measure the cognitive effects of their drugs, resulting in an increased likelihood of drug approval opportunities following the assessment of cognitive efficacy and safety. Constant work in research and development and related investments by pharmaceutical companies are also driving the market. Awareness of the disease and the number of diagnosed patients is increasing rapidly confirming the need for the development of therapeutics. Partnership efforts to develop novel treatments will also drive market growth. For instance, Genentech, a member of the Roche Group, collaborates with UCB to develop an anti-Tau antibody UCB0107, an ongoing clinical trial aimed at addressing the need for more effective approaches.
Drivers
With a growing elderly population, the prevalence of Alzheimer's disease is rising, driving demand for effective therapeutics.
Significant progress in understanding the pathophysiology of Alzheimer's disease is leading to the development of novel drugs and therapies.
Emerging technologies such as biomarkers and imaging techniques are enhancing early diagnosis and personalized treatment, fuelling the market.
Growing awareness and educational campaigns about Alzheimer's disease are leading to early diagnosis and a higher demand for therapeutic interventions.
The growth of the market is driven by the increasing prevalence of Alzheimer's disease. In the year 2023, about 55 million people were estimated to be affected with dementia in which Alzheimer's disease comprised 60-70% of all cases according to the World Health Organization (WHO). This is a significant rise in the number of people affected by Alzheimer's disease, as compared to previous years, thus, highlighting a growing public health concern. There are approximately 6.68 million people with Alzheimer's disease in the United States. The National Institute on Aging foresees the prevalence among older adults for Alzheimer's to nearly triple in just a period of the next 40 years due largely to the aging population. The increasing prevalence underlines the urgent need for effective therapeutic interventions and encourages intense investment in research and drug development programs. The upsurge in the number of Alzheimer's patients signals an increasing demand for advanced and effective treatment options, driving advancements within the global therapeutics market.
Restraints
The cost of developing and acquiring new Alzheimer's therapeutics can be prohibitively high, limiting access and affecting market growth.
Stringent regulatory requirements and lengthy approval processes can delay the launch of new drugs and impact market dynamics.
Many existing treatments offer only symptomatic relief and have limited effectiveness, which may impact patient and caregiver expectations.
High development and acquisition costs related to new Alzheimer's therapeutics mark one of the major restraints in the market. R&D for Alzheimer's drugs involve extensive clinical trials, testing on a wide scale, and regulatory mechanisms, which are usually resource-and time-consuming and costly. The treatment becomes less accessible to people, mainly those who do not have sufficient insurance coverage. the high cost of innovative drugs can strain healthcare systems and limit the adoption of new therapies. The economic barrier is compounded by the fact that many current therapies offer only modest benefits, further challenging the cost-benefit ratio and making it difficult for new, high-priced treatments to gain widespread acceptance.
By Product
The cholinesterase inhibitors held more than 48% revenue share in 2023 and leading product segment in the treatment of Alzheimer's due to its status as a standard of care. In March 2022, the U.S. FDA approved the Adlarity, donepezil hydrochloride a cholinesterase inhibitor from Corium Inc. for the symptomatic treatment of severe dementia in Alzheimer’s disease (AD). This transdermal patch provides a steady dosage of donepezil, and it represents the fourth cholinesterase drug approved in the U.S., which continues to reflect the reliance on this class of drugs in the management of AD.
The pipeline drugs segment is expected to witness the fastest growth in the coming years, driven by the imminent launch of several disease-modifying therapies. Major pharmaceutical companies such as F. Hoffmann-La Roche Ltd, Biogen/Eisai Inc., and Eli Lilly and Company have developed drug candidates that can bring a paradigm shift in the treatment of AD.
By End-user
The Alzheimer’s therapeutics market is led by hospital pharmacy segment with more than 56% revenue share in 2023, as an increase in geriatric population and rising patient of AD lead to a greater number of people getting hospitalized. In 2022, there are 518 hospitalizations per 1000 medicare beneficiaries or other dementias, compared to 234 hospitalizations per 1,000 medicare beneficiaries without these conditions. This disparity underscores the higher rates of hospitalization in Alzheimer's patients but, relative to overall disease prevalence levels, total numbers are relatively low.
E-commerce segment is projected to grow with significant CAGR over a period of forecast. This growth is accompanied by greater penetration of the internet and smartphones, enabling patients and their caretakers to order medicines more smoothly online. The convenience provided by the e-commerce platform, may be considered as some of the prominent factors for the growth of the segment, along with the expansion of the e-commerce services globally. This means that, with an increasing dependence on online channels to meet their healthcare requirements, the e-commerce segment is very likely to grow in significance as a distribution channel for Alzheimer's therapeutics in the future, offering access and convenience to an expanding patient-caregiver base. Moreover, this move toward digital platforms will imply wider availability of Alzheimer's medications, which will also continue to drive market growth in this space.
Need any customization research on Alzheimer’s Therapeutics Market- Enquiry Now
Intensive research activities and remarkable achievements concerning treatment made North America to dominate the Alzheimer's therapeutics market in 2023 which held more than 38% revenue share. In June 2021, the US FDA designated Breakthrough Therapy status to lecanemab (BAN2401) developed by Eisai Co., Ltd. and Biogen. An anti-amyloid beta protofibril antibody, it is intended for the treatment of Alzheimer's disease, therefore the region is committed to moving forward with the treatments. Besides, increasing government initiatives and funds are likely to further support market growth in the region of North America.
On the other side, the Asia Pacific is expected to grow with the fastest annual growth rate during the forecast period, due to the higher awareness about Alzheimer's disease and due to intense research activities oriented toward new therapeutic options. In fact, it is estimated by the Australian Institute of Health and Welfare that there were 411,100 people living with dementia in Australia alone in 2023, with this number expected to double by 2058. With dementia already being the second leading cause of death in the country at the moment, there is actually an urgent need for effective therapeutic solutions. This will be a crucial area of future demand and market expansion for treatments of Alzheimer's disease, as dementia is an increasingly prevalent factor throughout the Asia Pacific region.
The major players in market are Eisai Co., Ltd., Daiichi Sankyo Company, Novartis AG, AbbVie Inc. (Allergan Plc.), Adamas Pharmaceuticals, Inc., H. Lundbeck A/S, F. Hoffmann La Roche Ltd., Biogen, TauRx Pharmaceuticals Ltd., AC Immune, Limited, Johnson & Johnson Services, Inc., And others in final report.
FDA approved Eisai Co., Ltd.'s Leqembi for the treatment of Alzheimer's disease. The medication, lecanemab-irmb, was used to reduce amyloid-β plaques and, in addition, provide standard medical care to moderately delay cognitive decline in early Alzheimer's patients, In January 2023. Success with these treatments will be highly expected to lead to further market growth.
The deal to collaborate with Eisai Co. was extended in March 2022, in an attempt to better the possibility of opening new therapeutic avenues for Alzheimer disease too.
Positive results of a Phase III large-scale clinical study of its investigational anti-amyloid drug, Donanemab, were announced by Eli Lilly and Company in March 2023. The trial showed that Donanemab arrested cognitive and functional decline in sufferers of early Alzheimer's.
Biogen Inc. and Eisai Co. announced interim results from a Phase 3 trial for the Alzheimer's drug Aducanumab, targeting amyloid plaques, in June 2023. The data showed Aducanumab could have clinical benefits in early Alzheimer's disease and thus gave reason for discussing the regulatory approval.
August 2023, F.D.A. Approves New Combination Therapy for Alzheimer's Cholinesterase inhibitor/Nmda Receptor Antagonist: two-pronged strategy designed to attack the cognitive and functional components of Alzheimer's disease.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 3.78 Billion |
| Market Size by 2032 | USD 13.42 Billion |
| CAGR | CAGR of 15.14% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Cholinesterase inhibitors {Donepezil, Galantamine, Rivastigmine}, NMDA Receptor Antagonist, Pipeline Drugs, Combination Drug) • By End-user (Hospital Pharmacy, E-commerce, Retail Pharmacy) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe[ Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Eisai Co., Ltd., Daiichi Sankyo Company, Novartis AG, AbbVie Inc. (Allergan Plc.), Adamas Pharmaceuticals, Inc., H. Lundbeck A/S, F. Hoffmann La Roche Ltd., Biogen, TauRx Pharmaceuticals Ltd., AC Immune, Limited, Johnson & Johnson Services, Inc |
| Key Drivers | • With a growing elderly population, the prevalence of Alzheimer's disease is rising, driving demand for effective therapeutics. • Significant progress in understanding the pathophysiology of Alzheimer's disease is leading to the development of novel drugs and therapies. |
| RESTRAINTS | • The cost of developing and acquiring new Alzheimer's therapeutics can be prohibitively high, limiting access and affecting market growth. |
Ans. The projected market size for the Alzheimer’s Therapeutics Market is USD 13.42 billion by 2032.
Ans: The North American region dominated the Alzheimer’s Therapeutics Market in 2023, with a 38% share.
Ans: The Hospital Pharmacy end user segment dominated the Alzheimer’s Therapeutics Market.
Ans. The CAGR of the Alzheimer’s Therapeutics Market is 15.14% During the forecast period of 2024-2032.
Ans: Yes, you can customize the report as per your requirements.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Device Volume, by Region (2020-2032)
5.4 Healthcare Spending, by region, (Government, Commercial, Private, Out-of-Pocket), 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Alzheimer’s Therapeutics Market Segmentation, by Product
7.1 Chapter Overview
7.2 Cholinesterase inhibitors
7.2.1 Cholinesterase inhibitors Market Trends Analysis (2020-2032)
7.2.2 Cholinesterase inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Donepezil
7.2.3.1 Donepezil Market Trends Analysis (2020-2032)
7.2.3.2 Donepezil Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Galantamine
7.2.4.1 Galantamine Market Trends Analysis (2020-2032)
7.2.4.2 Galantamine Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.5 Rivastigmine
7.2.5.1 Rivastigmine Market Trends Analysis (2020-2032)
7.2.5.2 Rivastigmine Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 NMDA Receptor Antagonist
7.3.1 NMDA Receptor Antagonist Market Trends Analysis (2020-2032)
7.3.2 NMDA Receptor Antagonist Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Pipeline Drugs
7.4.1 Pipeline Drugs Market Trends Analysis (2020-2032)
7.4.2 Pipeline Drugs Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Combination Drug
7.5.1 Combination Drug Market Trends Analysis (2020-2032)
7.5.2 Combination Drug Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Alzheimer’s Therapeutics Market Segmentation, by End User
8.1 Chapter Overview
8.2 Hospital Pharmacy
8.2.1 Hospital Pharmacy Market Trends Analysis (2020-2032)
8.2.2 Hospital Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 E-commerce
8.3.1 E-commerce Market Trends Analysis (2020-2032)
8.3.2 E-commerce Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Retail Pharmacy
8.4.1 Retail Pharmacy Market Trends Analysis (2020-2032)
8.4.2 Retail Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Alzheimer’s Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.4 North America Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.5.2 USA Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.6.2 Canada Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.7.2 Mexico Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Alzheimer’s Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.5.2 Poland Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.6.2 Romania Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Alzheimer’s Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.4 Western Europe Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.5.2 Germany Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.6.2 France Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.7.2 UK Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.8.2 Italy Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.9.2 Spain Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.12.2 Austria Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Alzheimer’s Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.4 Asia Pacific Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.5.2 China Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.5.2 India Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.5.2 Japan Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.6.2 South Korea Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.7.2 Vietnam Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.8.2 Singapore Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.9.2 Australia Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Alzheimer’s Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.4 Middle East Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.5.2 UAE Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Alzheimer’s Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.4 Africa Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Alzheimer’s Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.4 Latin America Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.5.2 Brazil Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.6.2 Argentina Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.7.2 Colombia Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Alzheimer’s Therapeutics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Alzheimer’s Therapeutics Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10. Company Profiles
10.1 Eisai Co., Ltd.
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Daiichi Sankyo Company
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Novartis AG
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Va AbbVie Inc. (Allergan Plc.)
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Adamas Pharmaceuticals, Inc.
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 H. Lundbeck A/S
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 F. Hoffmann La Roche Ltd.
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Biogen
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 TauRx Pharmaceuticals Ltd.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 AC Immune
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Product
Cholinesterase inhibitors
Donepezil
Galantamine
Rivastigmine
NMDA Receptor Antagonist
Pipeline Drugs
Combination Drug
By End-user
Hospital Pharmacy
E-commerce
Retail Pharmacy
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Personal Mobility Device Market size was valued at USD 12.35 billion in 2023 and is expected to reach USD 23.48 billion by 2032, growing at a CAGR of 7.37% over the forecast period of 2024-2032.
The Bispecific Antibodies Market size was estimated at USD 8.24 billion in 2023 and is expected to reach USD 153.23 billion by 2031 with a growing CAGR of 44.1% during the forecast period of 2024-2031.
Our team at SNS Insider is in the final stages of compiling the upcoming report on the Companion Animal Vaccines Market, which will be released soon.
The Computerized Physician Order Entry Market Size was valued at USD 1.81 billion in 2023, and expected to reach USD 3.25 billion by 2032, and grow at a CAGR of 6.7% over the forecast period 2024-2032.
The global Healthcare Supply Chain Management Market, valued at USD 2.76 billion in 2023, with a projected growth to USD 9.72 billion by 2032 at a CAGR of 15.04%
The Veterinary Digital Pathology Market was valued at 0.8 Bn in 2023 and is expected to reach 2.64 Bn by 2031 and grow at a CAGR of 12.9% over the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
